New CAR-NK cell therapy takes on colorectal cancer

NCT ID NCT07462650

Recruiting now Disease control Sponsor: Beijing Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment made from donated cord blood cells that are engineered to recognize and attack colorectal cancer cells. It is for people with advanced or metastatic colorectal cancer that has not responded to standard treatments. The trial will check safety and early signs of effectiveness in 48 adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Allogeneic dual-target CAR-NK cells (engineered immune cells from donated cord blood) targeting CEA and/or GUCY2C, with an IL-15 support element and a safety switch
What this could lead to: If successful, this could point toward a new treatment option for advanced colorectal cancer that has stopped responding to standard therapies.
What could go wrong: This is an early phase 1/2 trial with only 48 participants, so results may not apply broadly. The treatment involves genetically modified cells, which could cause unexpected side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF COLON are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colonic neoplasm colorectal adenocarcinoma colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA OF COLON COLORECTAL CANCER METASTATIC

Contacts and locations

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.